Navigation Links
Viking Therapeutics to Present at Upcoming Life Science Industry Events
Date:11/12/2015

SAN DIEGO, Nov. 12, 2015 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming life science industry events. Details for these presentations are as follows:

  • Stifel Healthcare Conference 2015 – webcast available
    Time/Date:  2:15 – 2:55 p.m. ET on Tuesday, November 17, 2015
    Location:  The New York Palace Hotel, New York City
  • Ligand Pharmaceuticals Analyst Day  – webcast available
    Time/Date:  10:00 – 11:30 a.m. ET on Wednesday, November 18, 2015
    Location:  Le Parker Meridien Hotel, New York City

To access the live webcast of Viking's presentation at the Stifel conference, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.

The Ligand analyst day will be webcast live and can be accessed at www.ligand.com.  A replay of this webcast will be available for 90 days following the event.

About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.  The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.  Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.  The company's clinical programs include VK5211, an orally available, non-steroidal SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes.  Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.

Learn more at: www.vikingtherapeutics.com.

Forward Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, including statements about Viking's research and development activities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials; and risks regarding regulatory requirements, among others. These forward-looking statements speak only as of the date hereof.  Viking disclaims any obligation to update these forward-looking statements.

 


'/>"/>
SOURCE Viking Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
2. Myelofibrosis Pipeline Therapeutics Reviewed for H2 2015 in New Research
3. Tobira Therapeutics Reports Third Quarter 2015 Financial Results
4. Astellas to Acquire Ocata Therapeutics
5. PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD
6. UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy
7. Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate
8. Clinical Data Featuring Trovagenes Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
10. Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022 - Reportlinker Review
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... Gwinnett Family Dental Care , located at ... complete dental care, including general and preventative care as well as restorative and ... of extensively trained dentists, Dr. Kell Gallaher, Dr. Jon Klevansky, Dr. Jason Klevansky, Dr. ...
(Date:7/17/2019)... ... July 17, 2019 , ... As the healthcare ... strategies to keep pathologists, laboratory professionals and residents on the forefront of the ... patient care. , Renowned Speakers Covering Crucial Topics , On September 11, ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... has announced the Best Assisted Living Communities in New York City. The ... affordability and more.     , AssistedLiving.org used a unique selection process which involved ...
Breaking Medicine Technology:
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... solutions to health plans participating in Medicare Advantage, Medicaid, and Marketplace programs is ... for Providers featuring Electronic Health Records (EHR) integration at the point ...
(Date:7/17/2019)... ... July 17, 2019 , ... It took just several small ... Martinez, MD, to relieve pressure on the nerves under Amber Walck’s scalp, and suddenly ... woman turned 30 last year, her debilitating headaches began without warning. About 39 ...
(Date:7/17/2019)... Ontario (PRWEB) , ... July 17, 2019 , ... ... management software and client engagement options for human services providers worldwide, has been ... , The CMAS program streamlines the procurement process for state and local government ...
(Date:7/17/2019)... SAN DIEGO (PRWEB) , ... July 17, 2019 , ... ... not become parents. Every Intended Parents’ story differs , but, in addition to ... their Surrogate. , Across the globe, more and more Intended Parents are electing to ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... York State ( COMPA ) today announced that seven of its member Opioid ... the treatment of substance abuse and hepatitis C virus (HCV) with the goal ...
Breaking Medicine News(10 mins):